PAGSEG Inc vs Zoetis Inc — how do they compare? PAGSEG Inc trades at $9.69 (market cap $2.68B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 11.8× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.86%). Which is the better fit depends on your goals.
| PAGS | ZTS | |
|---|---|---|
Market Cap | $2.68B | $31.59B |
Sector | Technology | Health |
52-Week High | $12.00 | $156.76 |
52-Week Low | $7.75 | $71.91 |
Enterprise Value | $10.42B | $38.89B |
Dividend Yield | 10.86% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.29, up 2.77% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 6.57 and P/S of 0.68, trading below book value. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 2026 missing estimates. The company maintains strong profitability with 10.4% net margin and robust cash flow generation of $7.56B from operations in 2025.
Analyst consensus remains strongly bullish with 62.5% buy ratings, though Brazilian macroeconomic risks and competitive pressures warrant monitoring. The stock presents value opportunity with deep discount valuation while benefiting from Brazil's digital banking growth, though execution on credit expansion and funding costs remain key catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →